Correspondence 0001501697-26-000046 from X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc
Date: May 12, 2026 · CIK: 0001501697 · Accession: 0001501697-26-000046
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295597
Letter
Document X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4th Floor Boston, MA 02134 May 12, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: X4 Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-295597) Ladies and Gentlemen: X4 Pharmaceuticals, Inc. hereby respectfully requests that, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective on May 14, 2026, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631. Sincerely, X4 PHARMACEUTICALS, INC By: /s/ David Kirske_________________ David Kirske Chief Financial Officer and Secretary cc: Adam R. Craig, M.D., Ph.D., X4 Pharmaceuticals, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP
Show Raw Text
CORRESP 1 filename1.htm Document X4 Pharmaceuticals, Inc. 61 North Beacon Street, 4th Floor Boston, MA 02134 May 12, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jessica Dickerson Re: X4 Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-295597) Ladies and Gentlemen: X4 Pharmaceuticals, Inc. hereby respectfully requests that, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective on May 14, 2026, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631. Sincerely, X4 PHARMACEUTICALS, INC By: /s/ David Kirske_________________ David Kirske Chief Financial Officer and Secretary cc: Adam R. Craig, M.D., Ph.D., X4 Pharmaceuticals, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP